NICE: molecules with a published decision record
306 molecules on this site carry at least one NICE decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| adalimumab | 133 | 11 | Immunosuppressants |
| atezolizumab | 120 | 14 | Antineoplastics |
| dupilumab | 116 | 15 | Other dermatologicals |
| daratumumab | 115 | 15 | Antineoplastics |
| olaparib | 114 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| ibrutinib | 108 | 15 | Antineoplastics |
| rituximab | 94 | 9 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| secukinumab | 79 | 12 | Immunosuppressants |
| bevacizumab | 77 | 10 | Antineoplastics |
| tocilizumab | 76 | 12 | Immunosuppressants |
| ustekinumab | 71 | 11 | Immunosuppressants |
| infliximab | 69 | 9 | Immunosuppressants |
| lenalidomide | 68 | 13 | Immunosuppressants |
| aflibercept | 67 | 11 | Antineoplastics |
| denosumab | 67 | 11 | Bone diseases |
| osimertinib | 65 | 14 | Antineoplastics |
| blinatumomab | 64 | 14 | Antineoplastics |
| dapagliflozin | 64 | 12 | Diabetes |
| empagliflozin | 64 | 13 | Diabetes |
| trastuzumab deruxtecan | 64 | 14 | Antineoplastics |
| everolimus | 61 | 9 | Antineoplastics |
| venetoclax | 61 | 14 | Antineoplastics |
| tofacitinib | 60 | 13 | Immunosuppressants |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| ipilimumab | 58 | 14 | Antineoplastics |
| zanubrutinib | 58 | 16 | Antineoplastics |
| trastuzumab | 57 | 9 | Antineoplastics |
| cabozantinib | 56 | 15 | Antineoplastics |
| guselkumab | 56 | 13 | Immunosuppressants |
| risankizumab | 56 | 14 | Immunosuppressants |
| bimekizumab | 55 | 14 | Immunosuppressants |
| cemiplimab | 55 | 13 | Antineoplastics |
| rivaroxaban | 55 | 11 | Antithrombotics |
| brentuximab vedotin | 54 | 12 | Antineoplastics |
| ravulizumab | 54 | 15 | Immunosuppressants |
| selpercatinib | 53 | 13 | Antineoplastics |
| semaglutide | 53 | 14 | Diabetes |
| acalabrutinib | 52 | 14 | Antineoplastics |
| enzalutamide | 52 | 12 | Endocrine therapy |
| ribociclib | 50 | 14 | Antineoplastics |
| ruxolitinib | 50 | 12 | Antineoplastics |
| lenvatinib | 49 | 14 | Antineoplastics |
| nintedanib | 49 | 15 | Antineoplastics |
| baricitinib | 48 | 14 | Immunosuppressants |
| tislelizumab | 48 | 12 | Antineoplastics |
| abemaciclib | 47 | 15 | Antineoplastics |
| amivantamab | 47 | 13 | Antineoplastics |
| vedolizumab | 44 | 12 | Immunosuppressants |
| certolizumab pegol | 43 | 11 | Immunosuppressants |
| golimumab | 43 | 10 | Immunosuppressants |
| omalizumab | 43 | 12 | Obstructive airway diseases |
| avelumab | 42 | 13 | Antineoplastics |
| niraparib | 42 | 15 | Antineoplastics |
| aripiprazole | 41 | 8 | Psycholeptics |
| ixekizumab | 41 | 11 | Immunosuppressants |
| ranibizumab | 41 | 10 | Ophthalmologicals |
| dostarlimab | 39 | 14 | Antineoplastics |
| eculizumab | 39 | 11 | Immunosuppressants |
| evolocumab | 39 | 11 | Lipid modifying agents |
| dabrafenib | 38 | 14 | Antineoplastics |
| darolutamide | 38 | 15 | Endocrine therapy |
| isatuximab | 38 | 12 | Antineoplastics |
| alectinib | 37 | 15 | Antineoplastics |
| alirocumab | 37 | 13 | Lipid modifying agents |
| obinutuzumab | 37 | 12 | Antineoplastics |
| tisagenlecleucel | 37 | 12 | Antineoplastics |
| cannabidiol | 35 | 12 | Antiepileptics |
| crizotinib | 35 | 12 | Antineoplastics |
| abatacept | 34 | 10 | Immunosuppressants |
| axicabtagene ciloleucel | 34 | 12 | Antineoplastics |
| burosumab | 34 | 13 | Bone diseases |
| cetuximab | 34 | 9 | Antineoplastics |
| esketamine | 33 | 13 | Psychoanaleptics |
| natalizumab | 33 | 12 | Immunosuppressants |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| carfilzomib | 32 | 11 | Antineoplastics |
| pertuzumab | 32 | 13 | Antineoplastics |
| apixaban | 31 | 11 | Antithrombotics |
| benralizumab | 31 | 15 | Obstructive airway diseases |
| bortezomib | 31 | 7 | Antineoplastics |
| canakinumab | 31 | 10 | Immunosuppressants |
| liraglutide | 31 | 9 | Diabetes |
| ramucirumab | 31 | 9 | Antineoplastics |
| sacituzumab govitecan | 31 | 15 | Antineoplastics |
| avapritinib | 30 | 11 | Antineoplastics |
| entrectinib | 30 | 13 | Antineoplastics |
| fingolimod | 30 | 12 | Immunosuppressants |
| idelalisib | 30 | 8 | Antineoplastics |
| imatinib | 30 | 6 | Antineoplastics |
| regorafenib | 30 | 12 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| palbociclib | 29 | 13 | Antineoplastics |
| sofosbuvir | 29 | 11 | Antivirals |
| apalutamide | 28 | 12 | Endocrine therapy |
| apremilast | 28 | 10 | Immunosuppressants |
| belimumab | 28 | 12 | Immunosuppressants |